A six-metabolite blood biomarker achieved 85% accuracy in distinguishing Parkinson's disease from multiple system atrophy and progressive supranuclear palsy—conditions that frequently confound early diagnosis. The test uses nuclear magnetic resonance to measure specific metabolites in blood serum, with enhanced performance when VLDL-5 free cholesterol and citrate are included, reaching 95% accuracy versus healthy controls. This addresses a critical clinical gap, as Parkinson's diagnosis currently relies on symptom observation that often overlaps with other parkinsonian syndromes, leading to delayed or incorrect treatment decisions. The biomarker's successful translation to a standardized clinical platform represents a significant advancement toward routine diagnostic use. However, the study's modest sample sizes (30 patients per condition) and single-center design limit generalizability. As this is a preprint awaiting peer review, the promising results require validation through larger multicenter trials before clinical implementation. If confirmed, this could transform early Parkinson's care by enabling precise diagnosis at the de novo stage, when therapeutic interventions may be most effective for preserving neurological function and quality of life.